<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583063</url>
  </required_header>
  <id_info>
    <org_study_id>15328B</org_study_id>
    <nct_id>NCT00583063</nct_id>
  </id_info>
  <brief_title>Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers</brief_title>
  <official_title>A Pharmacokinetic Interaction Study of Rapamycin (Sirolimus) and SU11248 (Sunitinib) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the pharmacokinetic interactions between rapamycin and sunitinib in patients with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interactions</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the combined drug regimen</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to drug regimen</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>25 mg daily (oral dosing)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>4 mg daily (oral dosing)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or unresectable cancer for which standard treatments do not exist or are no
             longer effective or cancers where evidence of efficacy of single agent sunitinib or
             single agent mTOR inhibitor has been demonstrated

          -  Measurable or non-measurable disease.

          -  No prior treatments for 4 weeks before starting study

          -  No ongoing toxicities from previous treatments

          -  18 years or older

          -  Performance status 2 or better

          -  Life expectancy of at least 3 months.

          -  Normal organ and marrow function as defined below:

               -  No transfusions of packed red blood cells within 1 week of starting treatment. A
                  hemoglobin of 9.0 g/dL or greater is recommended. Patients should not be
                  transfused for protocol participation.

               -  Leukocytes greater than or equal to 3,000/μL

               -  Absolute neutrophil count greater than or equal to 1,500/μL

               -  Platelets greater than or equal to 100,000/μL

               -  Total bilirubin less than or equal to 1.5 x ULN

               -  AST and ALT less than or equal to 2.5x ULN (less than or equal to 5x ULN if liver
                  function abnormalities are due to underlying disease)

               -  Creatinine within normal institutional limits OR

               -  Creatinine clearance &gt; 60 mL/min/1.73 m2

               -  PT or INR within normal institutional limits

               -  Serum calcium within normal institutional limits

          -  QTc &lt; 500 msec.

          -  Patients with prior anthracycline exposure or that have received central thoracic
             radiation must have NYHA class I cardiac function

          -  Must agree to use adequate birth control

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Prior treatments within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of entering
             the study or those who have not recovered from adverse events due prior treatments

          -  Current treatment with other investigational agents.

          -  Prior therapy with a VEGFR or mTOR inhibitor

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to rapamycin or sunitinib.

          -  QTc prolongation (QTc interval equal to or greater than 500 msec) or other significant
             ECG abnormalities

          -  Uncontrolled intercurrent illness or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Patients with any of the following conditions are excluded:

               -  Serious or non-healing wound, ulcer, or bone fracture.

               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
                  abscess within 28 days of treatment.

               -  Known active infection

               -  Major surgery or radiation therapy within 4 weeks of starting the study
                  treatment.

               -  NCI CTCAE Version 3.0 grade 3 hemorrhage within 4 weeks of starting the study
                  treatment.

               -  History of CVA or transient ischemic attack within 12 months prior to study
                  entry.

               -  History of myocardial infarction, cardiac arrhythmia, stable/unstable angina,
                  symptomatic congestive heart failure, or coronary/peripheral artery bypass graft
                  or stenting within 12 months prior to study entry.

               -  History of pulmonary embolism within the past 12 months.

               -  Class III or IV heart failure as defined by the NYHA functional classification
                  system

               -  Ongoing cardiac dysrhythmias

               -  Poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or
                  diastolic blood pressure of 90 mmHg or higher)

               -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained
                  in the normal range with medication

               -  History of interstitial lung disease

          -  Patients with severe immunodeficient states (as judged by the treating physician)

          -  Pregnancy or breastfeeding.

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for interactions with the study drugs

          -  Use of certain medications (as determined by the investigator)

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk or interfere with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

